Clemens Muehlan

发表

Accelerated Development of the Dual Orexin Receptor Antagonist ACT‐541468: Integration of a Microtracer in a First‐in‐Human Study

J. V. van Gerven, J. Dingemanse, Clemens Muehlan, 2018, Clinical pharmacology and therapeutics.

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders

Isabelle Zenklusen, J. Dingemanse, Clemens Muehlan, 2020, Expert opinion on drug metabolism & toxicology.

Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator

J. Dingemanse, Michael Meinel, Clemens Muehlan, 2022, Clinical pharmacology and therapeutics.

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

B. Berger, J. Dingemanse, Clemens Muehlan, 2021, Clinical and translational science.

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

J. Dingemanse, A. Krause, D. Lott, 2022, CPT: pharmacometrics & systems pharmacology.

The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468

J. V. van Gerven, R. de Kanter, M. von Raumer, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist

S. Krähenbühl, B. Berger, U. Duthaler, 2021, Clinical Pharmacokinetics.

Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration

J. V. van Gerven, J. Dingemanse, Clemens Muehlan, 2020, Journal of psychopharmacology.

Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis

J. Dingemanse, M. Ufer, A. Krause, 2021, Clinical Drug Investigation.

Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration

J. V. van Gerven, J. Dingemanse, Clemens Muehlan, 2019, European Neuropsychopharmacology.

The orexin story and orexin receptor antagonists for the treatment of insomnia

J. Dingemanse, Clemens Muehlan, C. Roch, 2023, Journal of sleep research.

Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects

B. Berger, J. Dingemanse, Clemens Muehlan, 2020, CNS Drugs.

Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects.

J. Dingemanse, Clemens Muehlan, P. Peeters, 2020, Journal of clinical psychopharmacology.

The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin

Isabelle Zenklusen, J. Dingemanse, Clemens Muehlan, 2020, Clinical and experimental pharmacology & physiology.

Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry.

J. V. van Gerven, S. Krähenbühl, D. Zimmer, 2019, Current drug metabolism.

Metabolite profiling in early clinical drug development: current status and future prospects

Jasper Dingemanse, J. Dingemanse, M. Ufer, 2017, Expert opinion on drug metabolism & toxicology.